-
1
-
-
77951901715
-
Cell death in the pathogenesis of heart disease: Mechanisms and significance
-
Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 2010;72:19-44.
-
(2010)
Annu Rev Physiol
, vol.72
, pp. 19-44
-
-
Whelan, R.S.1
Kaplinskiy, V.2
Kitsis, R.N.3
-
5
-
-
0027967063
-
Reperfusion injury induces apoptosis in rabbit cardiomyocytes
-
Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994;94:1621-1628. (Pubitemid 24309885)
-
(1994)
Journal of Clinical Investigation
, vol.94
, Issue.4
, pp. 1621-1628
-
-
Gottlieb, R.A.1
Burleson, K.O.2
Kloner, R.A.3
Babior, B.M.4
Engler, R.L.5
-
6
-
-
1142309743
-
-
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway
-
Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004;61:448-460.
-
(2004)
Cardiovasc Res
, vol.61
, pp. 448-460
-
-
Hausenloy, D.J.1
Yellon, D.M.2
-
7
-
-
34548746306
-
Myocardial reperfusion injury
-
Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
-
(2007)
N Engl J Med
, vol.357
, pp. 1121-1135
-
-
Yellon, D.M.1
Hausenloy, D.J.2
-
8
-
-
34548008730
-
Reperfusion injury salvage kinase signalling: Taking a RISK for cardioprotection
-
DOI 10.1007/s10741-007-9026-1, Special Issue on Cardioprotection; Guest Editors: Dennis V. Cokkinos and Gerd Heusch
-
Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007;12:217-234. (Pubitemid 350176695)
-
(2007)
Heart Failure Reviews
, vol.12
, Issue.3-4
, pp. 217-234
-
-
Hausenloy, D.J.1
Yellon, D.M.2
-
11
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
DOI 10.1053/j.gastro.2007.03.054, PII S001650850700580X
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:2131-2157. (Pubitemid 46711096)
-
(2007)
Gastroenterology
, vol.132
, Issue.6
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
12
-
-
0028953577
-
Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
-
Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-957.
-
(1995)
J Clin Endocrinol Metab
, vol.80
, pp. 952-957
-
-
Deacon, C.F.1
Johnsen, A.H.2
Holst, J.J.3
-
13
-
-
0030607672
-
Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
-
DOI 10.1016/S0014-2999(96)00795-9, PII S0014299996007959
-
Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996;318:429-435. (Pubitemid 27046288)
-
(1996)
European Journal of Pharmacology
, vol.318
, Issue.2-3
, pp. 429-435
-
-
Knudsen, L.B.1
Pridal, L.2
-
14
-
-
78650753885
-
Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications
-
Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124:S3-S18.
-
(2011)
Am J Med
, vol.124
-
-
Nauck, M.A.1
-
15
-
-
67649637819
-
Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis
-
Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut 2009;58:990-997.
-
(2009)
Gut
, vol.58
, pp. 990-997
-
-
Marzioni, M.1
Alpini, G.2
Saccomanno, S.3
Candelaresi, C.4
Venter, J.5
Rychlicki, C.6
-
16
-
-
76449115696
-
Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection
-
Harkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 2010;159:495-501.
-
(2010)
Br J Pharmacol
, vol.159
, pp. 495-501
-
-
Harkavyi, A.1
Whitton, P.S.2
-
17
-
-
78649471913
-
Gastrointestinal hormones and the regulation of b-cell mass
-
Lavine JA, Attie AD. Gastrointestinal hormones and the regulation of b-cell mass. Ann N Y Acad Sci 2010;1212:41-58.
-
(2010)
Ann N y Acad Sci
, vol.1212
, pp. 41-58
-
-
Lavine, J.A.1
Attie, A.D.2
-
18
-
-
77953931504
-
Clinical approaches to preserve beta-cell function in diabetes
-
Wajchenberg BL. Clinical approaches to preserve beta-cell function in diabetes. Adv Exp Med Biol 2010;654:515-535.
-
(2010)
Adv Exp Med Biol
, vol.654
, pp. 515-535
-
-
Wajchenberg, B.L.1
-
19
-
-
23944479411
-
Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: Role of protein kinase B
-
DOI 10.1007/s00125-005-1787-2
-
Li L, El-KholyW, Rhodes CJ, Brubaker PL. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 2005;48:1339-1349. (Pubitemid 41186100)
-
(2005)
Diabetologia
, vol.48
, Issue.7
, pp. 1339-1349
-
-
Li, L.1
El-Kholy, W.2
Rhodes, C.J.3
Brubaker, P.L.4
-
20
-
-
79953173175
-
GLP-1-derived nonapeptide GLP-1(28-36) amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes
-
Tomas E, Stanojevic V, Habener JF. GLP-1-derived nonapeptide GLP-1(28-36) amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 2011;167:177-184.
-
(2011)
Regul Pept
, vol.167
, pp. 177-184
-
-
Tomas, E.1
Stanojevic, V.2
Habener, J.F.3
-
21
-
-
84860204551
-
Cardiovascular biology of the incretin system
-
doi:10.1210/er.2011-1052
-
Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33: doi:10.1210/er.2011-1052.
-
(2012)
Endocr Rev
, pp. 33
-
-
Ussher, J.R.1
Drucker, D.J.2
-
22
-
-
84859479993
-
Understanding the cardiovascular effects of incretin
-
Yoon JS, Lee HW. Understanding the cardiovascular effects of incretin. Diabetes Metab J 2011;35:437-443.
-
(2011)
Diabetes Metab J
, vol.35
, pp. 437-443
-
-
Yoon, J.S.1
Lee, H.W.2
-
23
-
-
79951884751
-
Glucagon-like peptide-1-based therapies and cardiovascular disease: Looking beyond glycaemic control
-
Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011;13:302-312.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 302-312
-
-
Anagnostis, P.1
Athyros, V.G.2
Adamidou, F.3
Panagiotou, A.4
Kita, M.5
Karagiannis, A.6
-
24
-
-
81855184473
-
The incretin axis in cardiovascular disease
-
Plutzky J. The incretin axis in cardiovascular disease. Circulation 2011;124:2285-2289.
-
(2011)
Circulation
, vol.124
, pp. 2285-2289
-
-
Plutzky, J.1
-
25
-
-
43249089631
-
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
-
DOI 10.1161/CIRCULATIONAHA.107.739938, PII 0000301720080506000007
-
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 2008;117:2340-2350. (Pubitemid 351653542)
-
(2008)
Circulation
, vol.117
, Issue.18
, pp. 2340-2350
-
-
Ban, K.1
Noyan-Ashraf, M.H.2
Hoefer, J.3
Bolz, S.-S.4
Drucker, D.J.5
Husain, M.6
-
26
-
-
0030013475
-
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
-
DOI 10.1210/en.137.7.2968
-
Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137: 2968-2978. (Pubitemid 26192194)
-
(1996)
Endocrinology
, vol.137
, Issue.7
, pp. 2968-2978
-
-
Bullock, B.P.1
Heller, R.S.2
Habener, J.F.3
-
27
-
-
0028900758
-
Tissue-specific expression of the human receptor for glucagon-like peptide-I: Brain, heart and pancreatic forms have the same deduced amino acid sequences
-
Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;358:219-224.
-
(1995)
FEBS Lett
, vol.358
, pp. 219-224
-
-
Wei, Y.1
Mojsov, S.2
-
28
-
-
0038577144
-
Cardiac function in mice lacking the glucagon-like peptide-1 receptor
-
DOI 10.1210/en.2003-0007
-
Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003;144: 2242-2252. (Pubitemid 36629873)
-
(2003)
Endocrinology
, vol.144
, Issue.6
, pp. 2242-2252
-
-
Gros, R.1
You, X.2
Baggio, L.L.3
Golam Kabir, M.4
Muktafi Sadi, A.5
Mungrue, I.N.6
Parker, T.G.7
Huang, Q.8
Drucker, D.J.9
Husain, M.10
-
29
-
-
12144260853
-
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
-
DOI 10.2337/diabetes.54.1.146
-
Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54: 146-151. (Pubitemid 40105106)
-
(2005)
Diabetes
, vol.54
, Issue.1
, pp. 146-151
-
-
Bose, A.K.1
Mocanu, M.M.2
Carr, R.D.3
Brand, C.L.4
Yellon, D.M.5
-
30
-
-
0035902451
-
Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo
-
Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001;104:330-335. (Pubitemid 32666956)
-
(2001)
Circulation
, vol.104
, Issue.3
, pp. 330-335
-
-
Matsui, T.1
Tao, J.2
Del Monte, F.3
Lee, K.-H.4
Li, L.5
Picard, M.6
Force, T.L.7
Franke, T.F.8
Hajjar, R.J.9
Rosenzweig, A.10
-
31
-
-
79960987925
-
Cardiovascular effects of glucagonlike peptide-1 agonists
-
Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol 2011;108:33B-41B.
-
(2011)
Am J Cardiol
, vol.108
-
-
Davidson, M.H.1
-
32
-
-
78649930490
-
GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats
-
Ku HC, Chen WP, Su MJ. GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn Schmiedebergs Arch Pharmacol 2010;382: 463-474.
-
(2010)
Naunyn Schmiedebergs Arch Pharmacol
, vol.382
, pp. 463-474
-
-
Ku, H.C.1
Chen, W.P.2
Su, M.J.3
-
33
-
-
77951168113
-
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice
-
Sauvé M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010;59:1063-1073.
-
(2010)
Diabetes
, vol.59
, pp. 1063-1073
-
-
Sauvé, M.1
Ban, K.2
Momen, M.A.3
Zhou, Y.Q.4
Henkelman, R.M.5
Husain, M.6
-
34
-
-
79961172510
-
DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion
-
Ku HC, Chen WP, Su MJ. DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol 2011;384:197-207.
-
(2011)
Naunyn Schmiedebergs Arch Pharmacol
, vol.384
, pp. 197-207
-
-
Ku, H.C.1
Chen, W.P.2
Su, M.J.3
-
35
-
-
84855171929
-
The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure
-
Hlebowicz J, Lindstedt S, Bjorgell O, Dencker M. The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure. Cardiovasc Ultrasound 2011;9:43.
-
(2011)
Cardiovasc Ultrasound
, vol.9
, pp. 43
-
-
Hlebowicz, J.1
Lindstedt, S.2
Bjorgell, O.3
Dencker, M.4
-
36
-
-
79851489434
-
Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men
-
Nathanson D, Zethelius B, Berne C, Lind L, Andrén B, Ingelsson E et al. Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men. Diabet Med 2011;28:301-305.
-
(2011)
Diabet Med
, vol.28
, pp. 301-305
-
-
Nathanson, D.1
Zethelius, B.2
Berne, C.3
Lind, L.4
Andrén, B.5
Ingelsson, E.6
-
37
-
-
10244254975
-
Apoptosis in myocytes in end-stage heart failure
-
DOI 10.1056/NEJM199610173351603
-
Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-1189. (Pubitemid 26339772)
-
(1996)
New England Journal of Medicine
, vol.335
, Issue.16
, pp. 1182-1189
-
-
Narula, J.1
Haider, N.2
Virmani, R.3
Disalvo, T.G.4
Kolodgie, F.D.5
Hajjar, R.J.6
Schmidt, U.7
Semigran, M.J.8
Dec, G.W.9
Khaw, B.-A.10
-
38
-
-
34848902937
-
2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure
-
DOI 10.1172/JCI31060
-
Nakayama H, Chen X, Baines CP, Klevitsky R, Zhang X, Zhang H et al. Ca2+-and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 2007;117:2431-2444. (Pubitemid 47494345)
-
(2007)
Journal of Clinical Investigation
, vol.117
, Issue.9
, pp. 2431-2444
-
-
Nakayama, H.1
Chen, X.2
Baines, C.P.3
Klevitsky, R.4
Zhang, X.5
Zhang, H.6
Jaleel, N.7
Chua, B.H.L.8
Hewett, T.E.9
Robbins, J.10
Houser, S.R.11
Molkentin, J.D.12
-
39
-
-
0032724201
-
Myocyte death in the failing human heart is gender dependent
-
Guerra S, Leri A,Wang X, Finato N, Di Loreto C, Beltrami CA et al. Myocyte death in the failing human heart is gender dependent. Circ Res 1999;85:856-866. (Pubitemid 29504161)
-
(1999)
Circulation Research
, vol.85
, Issue.9
, pp. 856-866
-
-
Guerra, S.1
Leri, A.2
Wang, X.3
Finato, N.4
Di Loreto, C.5
Beltrami, C.A.6
Kajstura, J.7
Anversa, P.8
-
40
-
-
77950267745
-
Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor
-
Ban K, Kim KH, Cho CK, Sauvé M, Diamandis EP, Backx PH et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010;151:1520-1531.
-
(2010)
Endocrinology
, vol.151
, pp. 1520-1531
-
-
Ban, K.1
Kim, K.H.2
Cho, C.K.3
Sauvé, M.4
Diamandis, E.P.5
Backx, P.H.6
-
41
-
-
58149342098
-
Effects and mechanism of glucagon-like peptide-1 on injury of rats cardiomyocytes induced by hypoxia-reoxygenation
-
Xie Y, Wang SX, Sha WW, Zhou X, Wang WL, Han LP et al. Effects and mechanism of glucagon-like peptide-1 on injury of rats cardiomyocytes induced by hypoxia-reoxygenation. Chin Med J (Engl) 2008;121:2134-2138.
-
(2008)
Chin Med J (Engl)
, vol.121
, pp. 2134-2138
-
-
Xie, Y.1
Wang, S.X.2
Sha, W.W.3
Zhou, X.4
Wang, W.L.5
Han, L.P.6
-
42
-
-
64649102619
-
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
-
Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975-983.
-
(2009)
Diabetes
, vol.58
, pp. 975-983
-
-
Noyan-Ashraf, M.H.1
Momen, M.A.2
Ban, K.3
Sadi, A.M.4
Zhou, Y.Q.5
Riazi, A.M.6
-
44
-
-
78649939959
-
Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury
-
Matsubara M, Kanemoto S, Leshnower BG, Albone EF, Hinmon R, Plappert T et al. Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury. J Surg Res 2011;165:38-45.
-
(2011)
J Surg Res
, vol.165
, pp. 38-45
-
-
Matsubara, M.1
Kanemoto, S.2
Leshnower, B.G.3
Albone, E.F.4
Hinmon, R.5
Plappert, T.6
-
45
-
-
58949084130
-
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
-
Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-510.
-
(2009)
J Am Coll Cardiol
, vol.53
, pp. 501-510
-
-
Timmers, L.1
Henriques, J.P.2
De Kleijn, D.P.3
Devries, J.H.4
Kemperman, H.5
Steendijk, P.6
-
46
-
-
80052072913
-
Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: Evidence for improving cardiac metabolic efficiency
-
Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One 2011;6:e23570.
-
(2011)
PLoS One
, vol.6
-
-
Bao, W.1
Aravindhan, K.2
Alsaid, H.3
Chendrimada, T.4
Szapacs, M.5
Citerone, D.R.6
-
47
-
-
78149300165
-
Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart
-
Brown SB, Libonati JR, Selak MA, Shannon RP, Simmons RA. Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart. Cardiovasc Drugs Ther 2010;24:197-205.
-
(2010)
Cardiovasc Drugs Ther
, vol.24
, pp. 197-205
-
-
Brown, S.B.1
Libonati, J.R.2
Selak, M.A.3
Shannon, R.P.4
Simmons, R.A.5
-
48
-
-
38149083367
-
Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart
-
Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146:243-249.
-
(2008)
Regul Pept
, vol.146
, pp. 243-249
-
-
Sonne, D.P.1
Engstrøm, T.2
Treiman, M.3
-
49
-
-
77953807602
-
Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits
-
Iwasa M, Kobayashi H, Yasuda S, Kawamura I, Sumi S, Yamada Y et al. Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits. J Cardiovasc Pharmacol 2010;55:625-634.
-
(2010)
J Cardiovasc Pharmacol
, vol.55
, pp. 625-634
-
-
Iwasa, M.1
Kobayashi, H.2
Yasuda, S.3
Kawamura, I.4
Sumi, S.5
Yamada, Y.6
-
50
-
-
79961231117
-
Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits
-
Iwasa M, Yamada Y, Kobayashi H, Yasuda S, Kawamura I, Sumi S et al. Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits. Br J Pharmacol 2011;164:119-131.
-
(2011)
Br J Pharmacol
, vol.164
, pp. 119-131
-
-
Iwasa, M.1
Yamada, Y.2
Kobayashi, H.3
Yasuda, S.4
Kawamura, I.5
Sumi, S.6
-
51
-
-
11844269899
-
Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines
-
DOI 10.1124/jpet.104.073890
-
Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen YT, Elahi D et al. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 2005;312:303-308. (Pubitemid 40096482)
-
(2005)
Journal of Pharmacology and Experimental Therapeutics
, vol.312
, Issue.1
, pp. 303-308
-
-
Nikolaidis, L.A.1
Doverspike, A.2
Hentosz, T.3
Zourelias, L.4
Shen, Y.-T.5
Elahi, D.6
Shannon, R.P.7
-
52
-
-
34548545405
-
Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway
-
DOI 10.1007/s10557-007-6030-6
-
Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 2007;21:253-256. (Pubitemid 47387464)
-
(2007)
Cardiovascular Drugs and Therapy
, vol.21
, Issue.4
, pp. 253-256
-
-
Bose, A.K.1
Mocanu, M.M.2
Carr, R.D.3
Yellon, D.M.4
-
53
-
-
77951812608
-
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
-
Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010;298: H1454-H1465.
-
(2010)
Am J Physiol Heart Circ Physiol
, vol.298
-
-
Ye, Y.1
Keyes, K.T.2
Zhang, C.3
Perez-Polo, J.R.4
Lin, Y.5
Birnbaum, Y.6
-
54
-
-
45349103305
-
Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia
-
Huisamen B, Genade S, Lochner A. Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. Cardiovasc J Afr 2008;19:77-83. (Pubitemid 351846438)
-
(2008)
Cardiovascular Journal of Africa
, vol.19
, Issue.2
, pp. 77-83
-
-
Huisamen, B.1
Genade, S.2
Lochner, A.3
-
55
-
-
79959966874
-
Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats
-
Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 2011;25: 13-20.
-
(2011)
Cardiovasc Drugs Ther
, vol.25
, pp. 13-20
-
-
Huisamen, B.1
Genis, A.2
Marais, E.3
Lochner, A.4
-
56
-
-
79955692561
-
Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents
-
Dokken BB, La Bonte LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res 2011; 43:300-305.
-
(2011)
Horm Metab Res
, vol.43
, pp. 300-305
-
-
Dokken, B.B.1
La Bonte, L.R.2
Davis-Gorman, G.3
Teachey, M.K.4
Seaver, N.5
McDonagh, P.F.6
-
57
-
-
77952889531
-
Glucagonlike peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction
-
Dokken BB, Hilwig WR, Teachey MK, Panchal RA, Hubner K, Allen D et al. Glucagonlike peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction. Resuscitation 2010;81:755-760.
-
(2010)
Resuscitation
, vol.81
, pp. 755-760
-
-
Dokken, B.B.1
Hilwig, W.R.2
Teachey, M.K.3
Panchal, R.A.4
Hubner, K.5
Allen, D.6
-
58
-
-
33646795007
-
Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts
-
DOI 10.1124/jpet.106.100982
-
Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006;317:1106-1113. (Pubitemid 43764114)
-
(2006)
Journal of Pharmacology and Experimental Therapeutics
, vol.317
, Issue.3
, pp. 1106-1113
-
-
Zhao, T.1
Parikh, P.2
Bhashyam, S.3
Bolukoglu, H.4
Poornima, I.5
Shen, Y.-T.6
Shannon, R.P.7
-
59
-
-
69049113026
-
Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model
-
Kristensen J, Mortensen UM, Schmidt M, Nielsen PH, Nielsen TT, Maeng M. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord 2009;9:31.
-
(2009)
BMC Cardiovasc Disord
, vol.9
, pp. 31
-
-
Kristensen, J.1
Mortensen, U.M.2
Schmidt, M.3
Nielsen, P.H.4
Nielsen, T.T.5
Maeng, M.6
-
60
-
-
0037629509
-
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium
-
DOI 10.1016/S0196-9781(03)00108-6
-
Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikström G et al. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 2003;24: 569-578. (Pubitemid 36829346)
-
(2003)
Peptides
, vol.24
, Issue.4
, pp. 569-578
-
-
Kavianipour, M.1
Ehlers, M.R.2
Malmberg, K.3
Ronquist, G.4
Ryden, L.5
Wikstrom, G.6
Gutniak, M.7
-
61
-
-
0019429079
-
Coronary collateral circulation in the pig: Correlation of collateral flow with coronary bed size
-
DOI 10.1007/BF01907957
-
White FC, Bloor CM. Coronary collateral circulation in the pig: correlation of collateral flow with coronary bed size. Basic Res Cardiol 1981;76:189-196. (Pubitemid 11102895)
-
(1981)
Basic Research in Cardiology
, vol.76
, Issue.2
, pp. 189-196
-
-
White, F.C.1
Bloor, C.M.2
-
62
-
-
80053358548
-
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
-
Yin M, Silljé HH, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 2011;10:85.
-
(2011)
Cardiovasc Diabetol
, vol.10
, pp. 85
-
-
Yin, M.1
Silljé, H.H.2
Meissner, M.3
Van Gilst, W.H.4
De Boer, R.A.5
-
63
-
-
84855492576
-
Granulocyte colony-stimulating factor treatment plus dipeptidylpeptidase- IV inhibition augments myocardial regeneration in mice expressing cyclin D2 in adult cardiomyocytes
-
Zaruba MM, Zhu W, Soonpaa MH, Reuter S, Franz WM, Field LJ. Granulocyte colony-stimulating factor treatment plus dipeptidylpeptidase-IV inhibition augments myocardial regeneration in mice expressing cyclin D2 in adult cardiomyocytes. Eur Heart J 2012;33:129-137.
-
(2012)
Eur Heart J
, vol.33
, pp. 129-137
-
-
Zaruba, M.M.1
Zhu, W.2
Soonpaa, M.H.3
Reuter, S.4
Franz, W.M.5
Field, L.J.6
-
64
-
-
58949102483
-
Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat
-
Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 2008;1:153-160.
-
(2008)
Circ Heart Fail
, vol.1
, pp. 153-160
-
-
Poornima, I.1
Brown, S.B.2
Bhashyam, S.3
Parikh, P.4
Bolukoglu, H.5
Shannon, R.P.6
-
65
-
-
78149493266
-
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
-
Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010;9:76.
-
(2010)
Cardiovasc Diabetol
, vol.9
, pp. 76
-
-
Liu, Q.1
Anderson, C.2
Broyde, A.3
Polizzi, C.4
Fernandez, R.5
Baron, A.6
-
66
-
-
4344605042
-
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
-
DOI 10.1161/01.CIR.0000139339.85840.DD
-
Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004;110:955-961. (Pubitemid 39128621)
-
(2004)
Circulation
, vol.110
, Issue.8
, pp. 955-961
-
-
Nikolaidis, L.A.1
Elahi, D.2
Hentosz, T.3
Doverspike, A.4
Huerbin, R.5
Zourelias, L.6
Stolarski, C.7
Shen, Y.-T.8
Shannon, R.P.9
-
67
-
-
28144441354
-
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
-
DOI 10.1152/ajpheart.00347.2005
-
Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289: H2401-H2408. (Pubitemid 41698549)
-
(2005)
American Journal of Physiology - Heart and Circulatory Physiology
, vol.289
, Issue.6
-
-
Nikolaidis, L.A.1
Elahi, D.2
Shen, Y.-T.3
Shannon, R.P.4
-
68
-
-
79951979265
-
Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy
-
Vyas AK, Yang KC, Woo D, Tzekov A, Kovacs A, Jay PY et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One 2011;6:e17178.
-
(2011)
PLoS One
, vol.6
-
-
Vyas, A.K.1
Yang, K.C.2
Woo, D.3
Tzekov, A.4
Kovacs, A.5
Jay, P.Y.6
-
69
-
-
84855317103
-
Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet
-
Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 2012;302:G225-G235.
-
(2012)
Am J Physiol Gastrointest Liver Physiol
, vol.302
-
-
Mells, J.E.1
Fu, P.P.2
Sharma, S.3
Olson, D.4
Cheng, L.5
Handy, J.A.6
-
70
-
-
0038202937
-
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
-
DOI 10.1097/00004872-200306000-00012
-
Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003;21: 1125-1135. (Pubitemid 36667866)
-
(2003)
Journal of Hypertension
, vol.21
, Issue.6
, pp. 1125-1135
-
-
Yu, M.1
Moreno, C.2
Hoagland, K.M.3
Dahly, A.4
Ditter, K.5
Mistry, M.6
Roman, R.J.7
-
71
-
-
81355124070
-
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy
-
Chaykovska L, von Websky K, Rahnenführer J, Alter M, Heiden S, Fuchs H et al. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One 2011;6:e27861.
-
(2011)
PLoS One
, vol.6
-
-
Chaykovska, L.1
Von Websky, K.2
Rahnenführer, J.3
Alter, M.4
Heiden, S.5
Fuchs, H.6
-
72
-
-
1442311383
-
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
-
DOI 10.1161/01.CIR.0000120505.91348.58
-
Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-965. (Pubitemid 38282847)
-
(2004)
Circulation
, vol.109
, Issue.8
, pp. 962-965
-
-
Nikolaidis, L.A.1
Mankad, S.2
Sokos, G.G.3
Miske, G.4
Shah, A.5
Elahi, D.6
Shannon, R.P.7
-
73
-
-
34547930879
-
Effect of Glucagon-Like Peptide-1 (GLP-1) on Glycemic Control and Left Ventricular Function in Patients Undergoing Coronary Artery Bypass Grafting
-
DOI 10.1016/j.amjcard.2007.05.022, PII S0002914907010491
-
Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr, Maher TD et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007;100:824-829. (Pubitemid 47268274)
-
(2007)
American Journal of Cardiology
, vol.100
, Issue.5
, pp. 824-829
-
-
Sokos, G.G.1
Bolukoglu, H.2
German, J.3
Hentosz, T.4
Magovern Jr., G.J.5
Maher, T.D.6
Dean, D.A.7
Bailey, S.H.8
Marrone, G.9
Benckart, D.H.10
Elahi, D.11
Shannon, R.P.12
-
74
-
-
84860390563
-
A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans
-
Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NE et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv 2011;4:266-272.
-
(2011)
Circ Cardiovasc Interv
, vol.4
, pp. 266-272
-
-
Read, P.A.1
Hoole, S.P.2
White, P.A.3
Khan, F.Z.4
O'Sullivan, M.5
West, N.E.6
-
75
-
-
84857111888
-
Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
-
Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 2012;98:408-413.
-
(2012)
Heart
, vol.98
, pp. 408-413
-
-
Read, P.A.1
Khan, F.Z.2
Dutka, D.P.3
-
76
-
-
84863560602
-
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
-
Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2011.
-
(2011)
Eur Heart J
-
-
Lønborg, J.1
Vejlstrup, N.2
Kelbæk, H.3
Bøtker, H.E.4
Kim, W.Y.5
Mathiasen, A.B.6
-
77
-
-
77951934948
-
DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease
-
Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010;3: 195-201.
-
(2010)
Circ Cardiovasc Imaging
, vol.3
, pp. 195-201
-
-
Read, P.A.1
Khan, F.Z.2
Heck, P.M.3
Hoole, S.P.4
Dutka, D.P.5
-
78
-
-
78650023641
-
Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)-rationale, design and first interim analysis
-
Theiss HD, Brenner C, Engelmann MG, Zaruba MM, Huber B, Henschel V et al. Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)- rationale, design and first interim analysis. Int J Cardiol 2010;145:282-284.
-
(2010)
Int J Cardiol
, vol.145
, pp. 282-284
-
-
Theiss, H.D.1
Brenner, C.2
Engelmann, M.G.3
Zaruba, M.M.4
Huber, B.5
Henschel, V.6
-
79
-
-
33644682164
-
Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure
-
Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Rydén L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 2004;1:40-43.
-
(2004)
Diab Vasc Dis Res
, vol.1
, pp. 40-43
-
-
Thrainsdottir, I.1
Malmberg, K.2
Olsson, A.3
Gutniak, M.4
Rydén, L.5
-
80
-
-
33845293219
-
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
-
DOI 10.1016/j.cardfail.2006.08.211, PII S1071916406011092
-
Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-699. (Pubitemid 44881367)
-
(2006)
Journal of Cardiac Failure
, vol.12
, Issue.9
, pp. 694-699
-
-
Sokos, G.G.1
Nikolaidis, L.A.2
Mankad, S.3
Elahi, D.4
Shannon, R.P.5
-
81
-
-
77749273703
-
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
-
Halbirk M, Nørrelund H, Møller N, Holst JJ, Schmitz O, Nielsen R et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010;298: H1096-H1102.
-
(2010)
Am J Physiol Heart Circ Physiol
, vol.298
-
-
Halbirk, M.1
Nørrelund, H.2
Møller, N.3
Holst, J.J.4
Schmitz, O.5
Nielsen, R.6
-
82
-
-
79951702236
-
Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: A retrospective analysis of the LifeLink database
-
Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011;34:90-95.
-
(2011)
Diabetes Care
, vol.34
, pp. 90-95
-
-
Best, J.H.1
Hoogwerf, B.J.2
Herman, W.H.3
Pelletier, E.M.4
Smith, D.B.5
Wenten, M.6
-
83
-
-
80455158258
-
Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): Study protocol for a randomized controlled trial
-
Scholte M, Timmers L, Bernink FJ, Denham RN, Beek AM, Kamp O et al. Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial. Trials 2011;12:240.
-
(2011)
Trials
, vol.12
, pp. 240
-
-
Scholte, M.1
Timmers, L.2
Bernink, F.J.3
Denham, R.N.4
Beek, A.M.5
Kamp, O.6
-
84
-
-
79957634425
-
Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes
-
Ovalle F. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Clin Ther 2011;33:393-407.
-
(2011)
Clin Ther
, vol.33
, pp. 393-407
-
-
Ovalle, F.1
-
85
-
-
79955397107
-
Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies
-
Giorgino F, Leonardini A, Natalicchio A, Laviola L. Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. J Endocrinol Invest 2011;34:69-77.
-
(2011)
J Endocrinol Invest
, vol.34
, pp. 69-77
-
-
Giorgino, F.1
Leonardini, A.2
Natalicchio, A.3
Laviola, L.4
|